|
1
|
Rosenberg SA: Raising the bar: The
curative potential of human cancer immunotherapy. Sci Transl Med.
4:127ps82012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kitamura T, Qian BZ and Pollard JW: Immune
cell promotion of metastasis. Nat Rev Immunol. 15:73–86. 2015.
View Article : Google Scholar
|
|
3
|
Ribas A and Wolchok JD: Cancer
immunotherapy using checkpoint blockade. Science. 359:1350–135.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun L, Zhang L, Yu J, Zhang Y, Pang X, Ma
C, Shen M, Ruan S, Wasan HS and Qiu S: Clinical efficacy and safety
of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or
metastatic cancer: A systematic review and meta-analysis. Sci Rep.
10:20832020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Curiel TJ: Regulatory T cells and
treatment of cancer. Curr Opin Immunol. 20:241–246. 2008.
View Article : Google Scholar
|
|
6
|
Shergold AL, Millar R and Nibbs RJB:
Understanding and overcoming the resistance of cancer to PD-1/PD-L1
blockade. Pharmacol Res. 145:1042582019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davis AA and Patel VG: The role of PD-L1
expression as a predictive biomarker: An analysis of all US food
and drug administration (FDA) approvals of immune checkpoint
inhibitors. J Immunother Cancer. 7:2782019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Postow MA, Callahan MK and Wolchok JD:
Immune checkpoint blockade in cancer therapy. J Clin Oncol.
33:1974–1982. 2015. View Article : Google Scholar
|
|
9
|
Wu M, Zhang Y, Zhang Y, Liu Y, Wu M and Ye
Z: Imaging-based Biomarkers for predicting and evaluating cancer
immunotherapy response. Radiol Imaging Cancer. 1:e1900312019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J,
Li J, Li F and Tan HB: Immune cells within the tumor
microenvironment: Biological functions and roles in cancer
immunotherapy. Cancer Lett. 470:126–133. 2020. View Article : Google Scholar
|
|
11
|
Ehrlich P: Über den jetzigen stand der
karzinomforschung. Ned Tijdshr Geneeskd. 5:273–290. 1909.
|
|
12
|
Burnet M: Cancer: A biological approach.
III. Viruses associated with neoplastic conditions. IV. Practical
applications. Br Med J. 1:841–847. 1957. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dunn GP, Old LJ and Schreiber RD: The
immunobiology of cancer immunosurveillance and immunoediting.
Immunity. 21:137–148. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thomas L: On immunosurveillance in human
cancer. Yale J Biol Med. 55:329–333. 1982.PubMed/NCBI
|
|
15
|
Kim R, Emi M and Tanabe K: Cancer
immunoediting from immune surveillance to immune escape.
Immunology. 121:1–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hodgkin PD: Modifying clonal selection
theory with a probabilistic cell. Immunol Rev. 285:249–262. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ribatti D: The concept of immune
surveillance against tumors. The first theories. Oncotarget.
8:7175–7180. 2017. View Article : Google Scholar
|
|
18
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and
Schreiber RD: Cancer immunoediting: From immunosurveillance to
tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar
|
|
19
|
Schreiber RD, Old LJ and Smyth MJ: Cancer
immunoediting: Integrating immunity's roles in cancer suppression
and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu W and Pasare C: Location, location,
location: Tissue-specific regulation of immune responses. J Leukoc
Biol. 94:409–421. 2013. View Article : Google Scholar
|
|
21
|
Bersanelli M and Buti S: From targeting
the tumor to targeting the immune system: Transversal challenges in
oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin
Oncol. 8:37–53. 2017. View Article : Google Scholar
|
|
22
|
Liang J, Balachandra S, Ngo S and O'Brien
LE: Feedback regulation of steady-state epithelial turnover and
organ size. Nature. 548:588–591. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lui PP, Cho I and Ali N: Tissue regulatory
T cells. Immunology. 161:4–17. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Klose CSN and Artis D: Innate lymphoid
cells control signaling circuits to regulate tissue-specific
immunity. Cell Res. 30:475–491. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schutte B and Ramaekers FC: Molecular
switches that govern the balance between proliferation and
apoptosis. Prog Cell Cycle Res. 4:207–217. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shechter R, London A and Schwartz M:
Orchestrated leukocyte recruitment to immune-privileged sites:
Absolute barriers versus educational gates. Nat Rev Immunol.
13:206–218. 2013. View Article : Google Scholar
|
|
27
|
Burzyn D, Benoist C and Mathis D:
Regulatory T cells in nonlymphoid tissues. Nat Immunol.
14:1007–1013. 2013. View Article : Google Scholar
|
|
28
|
Dong J, Chen Y, Xu X, Jin R, Teng F, Yan
F, Tang H, Li P, Sun X, Li Y, et al: Homeostatic properties and
phenotypic maturation of murine CD4+ pre-thymic emigrants in the
thymus. PLoS One. 8:e563782013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dobrzanski MJ: Expanding roles for CD4 T
cells and their subpopulations in tumor immunity and therapy. Front
Oncol. 3:632013. View Article : Google Scholar
|
|
30
|
Lee HM, Bautista JL, Scott-Browne J, Mohan
JF and Hsieh CS: A broad range of self-reactivity drives thymic
regulatory T cell selection to limit responses to self. Immunity.
37:475–486. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Geenen V: The thymus and the science of
self. Semin Immunopathol. 43:5–14. 2021. View Article : Google Scholar
|
|
32
|
Hsieh CS, Lee HM and Lio CW: Selection of
regulatory T cells in the thymus. Nat Rev Immunol. 12:157–167.
2012. View Article : Google Scholar
|
|
33
|
Muller WA: How endothelial cells regulate
transmigration of leukocytes in the inflammatory response. Am J
Pathol. 184:886–896. 2014. View Article : Google Scholar
|
|
34
|
Singh NK, Riley TP, Baker SCB, Borrman T,
Weng Z and Baker BM: Emerging concepts in TCR specificity:
Rationalizing and (Maybe) predicting outcomes. J Immunol.
199:2203–2213. 2017. View Article : Google Scholar
|
|
35
|
Sethna Z, Elhanati Y, Dudgeon CR, Callan
CG Jr, Levine AJ, Mora T and Walczak AM: Insights into immune
system development and function from mouse T-cell repertoires. Proc
Natl Acad Sci USA. 114:2253–2258. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Anders HJ, Romagnani P and Mantovani A:
Pathomechanisms: Homeostatic chemokines in health, tissue
regeneration, and progressive diseases. Trends Mol Med. 20:154–165.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Corrado C, Raimondo S, Chiesi A, Ciccia F,
De Leo G and Alessandro R: Exosomes as intercellular signaling
organelles involved in health and disease: Basic science and
clinical applications. Int J Mol Sci. 14:5338–5366. 2013.
View Article : Google Scholar
|
|
38
|
Senovilla L, Galluzzi L, Zitvogel L and
Kroemer G: Immunosurveillance as a regulator of tissue homeostasis.
Trends Immunol. 34:471–481. 2013. View Article : Google Scholar
|
|
39
|
Munoz MA, Biro M and Weninger W: T cell
migration in intact lymph nodes in vivo. Curr Opin Cell Biol.
30:17–24. 2014. View Article : Google Scholar
|
|
40
|
Mai J, Virtue A, Shen J, Wang H and Yang
XF: An evolving new paradigm: Endothelial cells-conditional innate
immune cells. J Hematol Oncol. 6:612013. View Article : Google Scholar
|
|
41
|
Ruddle NH: Lymphatic vessels and tertiary
lymphoid organs. J Clin Invest. 124:953–959. 2014. View Article : Google Scholar
|
|
42
|
Schaerli P, Ebert L, Willimann K, Blaser
A, Roos RS, Loetscher P and Moser B: A skin-selective homing
mechanism for human immune surveillance T cells. J Exp Med.
199:1265–1275. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Smigiel KS, Srivastava S, Stolley JM and
Campbell DJ: Regulatory T-cell homeostasis: Steady-state
maintenance and modulation during inflammation. Immunol Rev.
259:40–59. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Thiault N, Darrigues J, Adoue V, Gros M,
Binet B, Perals C, Leobon B, Fazilleau N, Joffre OP, Robey EA, et
al: Peripheral regulatory T lymphocytes recirculating to the thymus
suppress the development of their precursors. Nat Immunol.
16:628–634. 2015. View Article : Google Scholar
|
|
45
|
Fu H, Ward EJ and Marelli-Berg FM:
Mechanisms of T cell organotropism. Cell Mol Life Sci.
73:3009–3033. 2016. View Article : Google Scholar
|
|
46
|
Rothstein DM and Camirand G: New insights
into the mechanisms of Treg function. Curr Opin Organ Transplan.
20:376–384. 2015. View Article : Google Scholar
|
|
47
|
Mittelbrunn M and Sánchez-Madrid F:
Intercellular communication: Diverse structures for exchange of
genetic information. Nat Rev Mol Cell Biol. 13:328–335. 2012.
View Article : Google Scholar
|
|
48
|
Kouwaki T, Okamoto M, Tsukamoto H,
Fukushima Y and Oshiumi H: Extracellular vesicles deliver host and
virus RNA and regulate innate immune response. Int J Mol Sci.
18:6662017. View Article : Google Scholar
|
|
49
|
Villarroya-Beltri C, Gutiérrez-Vázquez C,
Sánchez-Cabo F, Pérez-Hernández D, Vázquez J, Martin-Cofreces N,
Martinez-Herrera DJ, Pascual-Montano A, Mittelbrunn M and
Sánchez-Madrid F: Sumoylated hnRNPA2B1 controls the sorting of
miRNAs into exosomes through binding to specific motifs. Nat
Commun. 4:29802013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Feng D, Zhao WL, Ye YY, Bai XC, Liu RQ,
Chang LF, Zhou Q and Sui SF: Cellular internalization of exosomes
occurs through phagocytosis. Traffic. 11:675–687. 2010. View Article : Google Scholar
|
|
51
|
Morelli AE, Larregina AT, Shufesky WJ,
Sullivan ML, Stolz DB, Papworth GD, Zahorchak AF, Logar AJ, Wang Z,
Watkins SC, et al: Endocytosis, intracellular sorting, and
processing of exosomes by dendritic cells. Blood. 104:3257–3266.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Colombo M, Raposo G and Théry C:
Biogenesis, secretion, and intercellular interactions of exosomes
and other extracellular vesicles. Annu Rev Cell Dev Biol.
30:255–289. 2014. View Article : Google Scholar
|
|
53
|
Mao X and Jin F: The exosome and breast
cancer cell plasticity. Onco Targets Ther. 12:9817–9825. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Green DR, Droin N and Pinkoski M:
Activation-induced cell death in T cells. Immunol Rev. 193:70–81.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ventimiglia LN and Alonso MA: Biogenesis
and function of T cell-derived exosomes. Front Cell Dev Biol.
4:842016. View Article : Google Scholar
|
|
56
|
Chinn IK, Blackburn CC, Manley NR and
Sempowski GD: Changes in primary lymphoid organs with aging. Semin
Immunol. 24:309–320. 2012. View Article : Google Scholar
|
|
57
|
Ucar O, Li K, Dvornikov D, Kreutz C,
Timmer J, Matt S, Brenner L, Smedley C, Travis MA, Hofmann TG, et
al: A thymic epithelial stem cell pool persists throughout ontogeny
and is modulated by TGF-β. Cell Rep. 17:448–457. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Geenen V, Trussart C, Michaux H, Halouani
A, Jaïdane H, Collée C, Renard C, Daukandt M, Ledent P and Martens
H: The presentation of neuroendocrine self-peptides in the thymus:
An essential event for individual life and vertebrate survival. Ann
NY Acad Sci. 1455:113–125. 2019. View Article : Google Scholar
|
|
59
|
Caton AJ, Kropf E, Simons DM, Aitken M,
Weissler KA and Jordan MS: Strength of TCR signal from self-peptide
modulates autoreactive thymocyte deletion and Foxp3(+) Treg-cell
formation. Eur J Immunol. 44:785–793. 2014. View Article : Google Scholar
|
|
60
|
Saran N, Łyszkiewicz M, Pommerencke J,
Witzlau K, Vakilzadeh R, Ballmaier M, von Boehmer H and Krueger A:
Multiple extrathymic precursors contribute to T-cell development
with different kinetics. Blood. 115:1137–1144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tang Q, Jiang D, Harfuddin Z, Cheng K, Moh
MC and Schwarz H: Regulation of myelopoiesis by CD137L signaling.
Int Rev Immunol. 33:454–469. 2014. View Article : Google Scholar
|
|
62
|
Medler TR and Coussens LM: Duality of the
immune response in cancer: Lessons learned from skin. J Invest
Dermatol. 134:E23–E28. 2014. View Article : Google Scholar
|
|
63
|
Egeblad M, Nakasone ES and Werb Z: Tumors
as organs: Complex tissues that interface with the entire organism.
Dev Cell. 18:884–901. 2010. View Article : Google Scholar
|
|
64
|
de Visser KE, Eichten A and Coussens LM:
Paradoxical roles of the immune system during cancer development.
Nat Rev Cancer. 6:24–37. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Re RN and Cook JL: An intracrine view of
angiogenesis. Bioessays. 28:943–953. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kumar P, Bhattacharya P and Prabhakar BS:
A comprehensive review on the role of co-signaling receptors and
Treg homeostasis in autoimmunity and tumor immunity. J Autoimmun.
95:77–99. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Seyfried TN and Huysentruyt LC: On the
origin of cancer metastasis. Crit Rev Oncog. 18:43–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Keskinov AA and Shurin MR: Myeloid
regulatory cells in tumor spreading and metastasis. Immunobiology.
220:236–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kovács KA, Hegedus B, Kenessey I and Tímár
J: Tumor type-specific and skin region-selective metastasis of
human cancers: Another example of the ‘seed and soil’ hypothesis.
Cancer Metastasis Rev. 32:493–499. 2013. View Article : Google Scholar
|
|
70
|
Caixeiro NJ, Kienzle N, Lim SH, Spring KJ,
Tognela A, Scott KF, de Souza P and Becker TM: Circulating tumour
cells-a bona fide cause of metastatic cancer. Cancer Metastasis
Rev. 33:747–756. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Ben-Baruch A: Organ selectivity in
metastasis: Regulation by chemokines and their receptors. Clin Exp
Metastasis. 25:345–356. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Satelli A, Mitra A, Brownlee Z, Xia X,
Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH and Li S:
Epithelial-mesenchymal transitioned circulating tumor cells capture
for detecting tumor progression. Clin Cancer Res. 21:899–906. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Sceneay J, Smyth MJ and Möller A: The
pre-metastatic niche: Finding common ground. Cancer Metastasis Rev.
32:449–464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Paduch R: The role of lymphangiogenesis
and angiogenesis in tumor metastasis. Cell Oncol (Dordr).
39:397–410. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Spinella F, Caprara V, Cianfrocca R,
Rosanò L, Di Castro V, Garrafa E, Natali PG and Bagnato A: The
interplay between hypoxia, endothelial and melanoma cells regulates
vascularization and cell motility through endothelin-1 and vascular
endothelial growth factor. Carcinogenesis. 35:840–848. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Horton BL and Gajewski TF: Back from the
dead: TIL apoptosis in cancer immune evasion. Br J Cancer.
118:309–311. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Smith HA and Kang Y: The
metastasis-promoting roles of tumor-associated immune cells. J Mol
Med (Berl). 91:411–429. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Lee JH, Chen Y, Chan JL, Qian YW and
Goydos JS: Molecular analysis of melanoma-induced sentinel lymph
node immune dysfunction. Cancer Immunol Immunother. 60:685–692.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Lagios MD: Clinical significance of
immunohistochemically detectable epithelial cells in sentinel lymph
node and bone marrow in breast cancer. J Surg Oncol. 83:1–4. 2003.
View Article : Google Scholar
|
|
81
|
Nishikawa H and Sakaguchi S: Regulatory T
cells in tumor immunity. Int J Cancer. 127:759–767. 2010.PubMed/NCBI
|
|
82
|
Sakaguchi S, Yamaguchi T, Nomura T and Ono
M: Regulatory T cells and immune tolerance. Cell. 133:775–787.
2008. View Article : Google Scholar
|
|
83
|
Brzostek J and Gascoigne NRJ: Thymic
origins of T cell receptor alloreactivity. Transplantation.
101:1535–1541. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Ariotti S, Beltman JB, Chodaczek G,
Hoekstra ME, Van Beek AE, Gomez-Eerland R, Ritsma L, van Rheenen J,
Marée AF, Zal T, et al: Tissue-resident memory CD8+ T cells
continuously patrol skin epithelia to quickly recognize local
antigen. Proc Natl Acad Sci USA. 109:19739–19744. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Deleeuw RJ, Kost SE, Kakal JA and Nelson
BH: The prognostic value of FoxP3+ tumor-infiltrating lymphocytes
in cancer: A critical review of the literature. Clin Cancer Res.
18:3022–3029. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Aggarwal S, Sharma SC and N Das S:
Dynamics of regulatory T cells (Tregs) in patients with
oral squamous cell carcinoma. J Surg Oncol. 116:1103–1113. 2017.
View Article : Google Scholar
|
|
87
|
Protti MP, De Monte L and Di Lullo G:
Tumor antigen-specific CD4+ T cells in cancer immunity: From
antigen identification to tumor prognosis and development of
therapeutic strategies. Tissue Antigens. 83:237–246. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Mailloux AW and Young MR: Regulatory
T-cell trafficking: From thymic development to tumor-induced immune
suppression. Crit Rev Immunol. 30:435–447. 2010. View Article : Google Scholar
|
|
89
|
Huang X, Chen Z, Zhang N, Zhu C, Lin X, Yu
J, Chen Z, Lan P and Wan Y: Increase in
CD4+FOXP3+ regulatory T cell number and
upregulation of the HGF/c-Met signaling pathway during the liver
metastasis of colorectal cancer. Oncol Lett. 20:2113–2118. 2020.
View Article : Google Scholar
|
|
90
|
Hamidinia M, Ghafourian Boroujerdnia M,
Talaiezadeh A, Solgi G, Roshani R, Iranprast S and Khodadadi A:
Increased P-35, EBI3 transcripts and other treg markers in
peripheral blood mononuclear cells of breast cancer patients with
different clinical stages. Adv Pharm Bull. 5:261–267. 2015.
View Article : Google Scholar
|
|
91
|
Vasco C, Canazza A, Rizzo A, Mossa A,
Corsini E, Silvani A, Fariselli L, Salmaggi A and Ciusani E:
Circulating T regulatory cells migration and phenotype in
glioblastoma patients: An in vitro study. J Neurooncol.
115:353–363. 2013. View Article : Google Scholar
|
|
92
|
Zhang X, Kelaria S, Kerstetter J and Wang
J: The functional and prognostic implications of regulatory T cells
in colorectal carcinoma. J Gastrointest Oncol. 6:307–313. 2015.
|
|
93
|
Chen X and Oppenheim JJ: Resolving the
identity myth: Key markers of functional CD4+FoxP3+ regulatory T
cells. Int Immunopharmacol. 11:1489–1496. 2011. View Article : Google Scholar
|
|
94
|
Ladoire S, Arnould L, Apetoh L, Coudert B,
Martin F, Chauffert B, Fumoleau P and Ghiringhelli F: Pathologic
complete response to neoadjuvant chemotherapy of breast carcinoma
is associated with the disappearance of tumor-infiltrating foxp3+
regulatory T cells. Clin Cancer Res. 14:2413–2420. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Teng MW, Ngiow SF, von Scheidt B,
McLaughlin N, Sparwasser T and Smyth MJ: Conditional regulatory
T-cell depletion releases adaptive immunity preventing
carcinogenesis and suppressing established tumor growth. Cancer
Res. 70:7800–7809. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Neophytou CM, Panagi M, Stylianopoulos T
and Papageorgis P: The role of tumor microenvironment in cancer
metastasis: Molecular mechanisms and therapeutic opportunities.
Cancers (Basel). 13:20532021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Baxevanis CN, Perez SA and Papamichail M:
Combinatorial treatments including vaccines, chemotherapy and
monoclonal antibodies for cancer therapy. Cancer Immunol
Immunother. 58:317–324. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Bhatia A and Kumar Y: Cellular and
molecular mechanisms in cancer immune escape: A comprehensive
review. Expert Rev Clin Immunol. 10:41–62. 2014. View Article : Google Scholar
|
|
99
|
Sasidharan Nair V and Elkord E: Immune
checkpoint inhibitors in cancer therapy: A focus on T-regulatory
cells. Immunol Cell Biol. 96:21–33. 2018. View Article : Google Scholar
|
|
100
|
Ruffell B, Denardo DG, Affara NI and
Coussens LM: Lymphocytes in cancer development: Polarization
towards pro-tumor immunity. Cytokine Growth Factor Rev. 21:3–10.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Rotte A, D'Orazi G and Bhandaru M: Nobel
committee honors tumor immunologists. J Exp Clin Cancer Res.
37:2622018. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Dolan DE and Gupta S: PD-1 pathway
inhibitors: Changing the landscape of cancer immunotherapy. Cancer
Control. 21:231–237. 2014. View Article : Google Scholar
|
|
103
|
Sharma P, Wagner K, Wolchok JD and Allison
JP: Novel cancer immunotherapy agents with survival benefit: Recent
successes and next steps. Nat Rev Cancer. 11:805–812. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Sharma A, Suleyman N, Jones O and Vasdev
N: Immunotherapy in urological tumors. Rev Urol. 21:15–20.
2019.
|
|
105
|
Steven A, Fisher SA and Robinson BW:
Immunotherapy for lung cancer. Respirology. 21:821–833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Dobosz P and Dzieciątkowski T: The
intriguing history of cancer immunotherapy. Front Immunol.
10:29652019. View Article : Google Scholar
|
|
107
|
Fritz JM and Lenardo MJ: Development of
immune checkpoint therapy for cancer. J Exp Med. 216:1244–1254.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Pennock GK and Chow LQ: The evolving role
of immune checkpoint inhibitors in cancer treatment. Oncologist.
20:812–822. 2015. View Article : Google Scholar
|
|
109
|
Ahern E, Solomon BJ, Hui R, Pavlakis N,
O'Byrne K and Hughes BGM: Neoadjuvant immunotherapy for non-small
cell lung cancer: Right drugs, right patient, right time? J
Immunother Cancer. 9:e0022482021. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Stege H, Haist M, Nikfarjam U, Schultheis
M, Heinz J, Pemler S, Loquai C and Grabbe S: The status of adjuvant
and neoadjuvant melanoma therapy, new developments and upcoming
challenges. Target Oncol. 16:537–552. 2021. View Article : Google Scholar
|
|
111
|
Signorelli D, Giannatempo P, Grazia G,
Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V,
Pisapia P, et al: Patients selection for immunotherapy in solid
tumors: Overcome the Naïve vision of a single biomarker. Biomed Res
Int. 2019:90564172019. View Article : Google Scholar
|
|
112
|
Zhu J, Powis de Tenbossche CG, Cané S,
Colau D, van Baren N, Lurquin C, Schmitt-Verhulst AM, Liljeström P,
Uyttenhove C and Van den Eynde BJ: Resistance to cancer
immunotherapy mediated by apoptosis of tumor-infiltrating
lymphocytes. Nat Commun. 8:14042017. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Horton BL, Williams JB, Cabanov A,
Spranger S and Gajewski TF: Intratumoral CD8+ T-cell
apoptosis is a major component of T-cell dysfunction and impedes
antitumor immunity. Cancer Immunol Res. 6:14–24. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Chaoul N, Tang A, Desrues B, Oberkampf M,
Fayolle C, Ladant D, Sainz-Perez A and Leclerc C: Lack of MHC class
II molecules favors CD8+ T-cell infiltration into tumors
associated with an increased control of tumor growth.
Oncoimmunology. 7:e14042132017. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Brunner-Weinzierl MC and Rudd CE: CTLA-4
and PD-1 control of T-cell motility and migration: Implications for
tumor immunotherapy. Front Immunol. 9:27372018. View Article : Google Scholar
|
|
116
|
Balkhi MY: Receptor signaling,
transcriptional, and metabolic regulation of T cell exhaustion.
Oncoimmunology. 9:17473492020. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Salmon H, Idoyaga J, Rahman A, Leboeuf M,
Remark R, Jordan S, Casanova-Acebes M, Khudoynazarova M, Agudo J,
Tung N, et al: Expansion and activation of CD103(+) dendritic cell
progenitors at the tumor site enhances tumor responses to
therapeutic PD-L1 and BRAF inhibition. Immunity. 44:924–938. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Li KP, Shanmuganad S, Carroll K, Katz JD,
Jordan MB and Hildeman DA: Dying to protect: Cell death and the
control of T-cell homeostasis. Immunol Rev. 277:21–43. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Paludan SR, Pradeu T, Masters SL and
Mogensen TH: Constitutive immune mechanisms: Mediators of host
defence and immune regulation. Nat Rev Immunol. 21:137–150. 2021.
View Article : Google Scholar
|
|
120
|
Fusi A and Dalgleish A: The importance for
immunoregulation for long-term cancer control. Future Oncol.
13:1619–1632. 2017. View Article : Google Scholar
|
|
121
|
Lisovska N and Shanazarov N: Tumor
progression mechanisms: Insights from the central immune regulation
of tissue homeostasis. Oncol Lett. 17:5311–5318. 2019.
|
|
122
|
Bruni D, Angell HK and Galon J: The immune
contexture and Immunoscore in cancer prognosis and therapeutic
efficacy. Nat Rev Cancer. 20:662–680. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Lecis D, Sangaletti S, Colombo MP and
Chiodoni C: Immune checkpoint ligand reverse signaling: Looking
back to go forward in cancer therapy. Cancers (Basel). 11:6242019.
View Article : Google Scholar
|
|
124
|
Rei M, Pennington DJ and Silva-Santos B:
The emerging protumor role of γδ T lymphocytes: Implications for
cancer immunotherapy. Cancer Res. 75:798–802. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Savage PA, Leventhal DS and Malchow S:
Shaping the repertoire of tumor-infiltrating effector and
regulatory T cells. Immunol Rev. 259:245–258. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Gourzones C, Barjon C and Busson P:
Host-tumor interactions in nasopharyngeal carcinomas. Semin Cancer
Biol. 22:127–136. 2012. View Article : Google Scholar
|
|
127
|
Fidler IJ: Lymphocytes are not only
immunocytes. Biomedicine. 32:1–3. 1980.PubMed/NCBI
|
|
128
|
Thomas VA and Balthasar JP: Understanding
inter-individual variability in monoclonal antibody disposition.
Antibodies (Basel). 8:562019. View Article : Google Scholar
|
|
129
|
Wolf D, Sopper S, Pircher A, Gastl G and
Wolf AM: Treg(s) in cancer: Friends or foe? J Cell Physiol.
230:2598–2605. 2015. View Article : Google Scholar
|
|
130
|
Sanmamed MF and Chen L: A paradigm shift
in cancer immunotherapy: From enhancement to normalization. Cell.
175:313–326. 2018. View Article : Google Scholar
|
|
131
|
Bedognetti D, Ceccarelli M, Galluzzi L, Lu
R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, et
al: Toward a comprehensive view of cancer immune responsiveness: A
synopsis from the SITC workshop. J Immunother Cancer. 7:1312019.
View Article : Google Scholar : PubMed/NCBI
|
